



INNOVATIVE PLATFORM FOR CANCER DIAGNOSIS

Powerful oncology diagnostic platform targeting multiple cancer applications

A unique assay allowing color discrimination between normal, pre-cancer and cancer cells alongside morphological examination. Highly sensitive detection of early-stage cancer tumors.

Non-invasive

Highly accurate

Early detection

Standard workflow

Cost-effective

Automatable



CellDetect® - A cutting-edge technology for early cancer detection

CellDetect® is an innovative technological platform targeting multiple cancer diagnostic applications, including cervical and bladder cancers. The CellDetect® platform is the only histochemical solution providing color discrimination between normal, pre-cancer and cancer cells alongside morphological examination. Highly sensitive for both low grade and high grade tumors, CellDetect® enables the diagnosis of early-stage tumors and pre-cancerous lesions which could otherwise be missed.

CellDetect® overview

- Based on well established technology
- Robust validated clinical data
- Strong global IP
- Peer-reviewed scientific publications
- Ready-to-market
- ISO certified facility (ISO 13485:2003)

Technological advantages


- Proprietary kit containing unique extract
- Applies standard staining laboratory processes & equipment
- Usable for many types of specimens
- Applicable to both liquid-based and conventional cytology
- Unique color-coding feature amenable for digital pathology

Bladder cancer monitoring test


- Designed to replace existing non-invasive tests which lack sensitivity mainly for early stage cancer tumors
- Potentially envisioned to replace cystoscopy procedures which are invasive and relatively expensive
- Sensitivity: 84%
- Specificity: 83%
- Regulatory approval: CE

Cervical cancer screening test

- Accurate, cost-effective and fast
- Sensitivity: 90-95%
- Specificity: 76-85%
- Regulatory approvals: CE, CFDA, AMAR
- Ready for commercialization



CellDetect® versus current technique



References:

- Davis et al. *Journal of Urology* 2014; 192:1628-1632
 He et al. *Gynecologic Oncology* 2014; 132:383-388
 Idelevich et al. *Diagnostic Cytopathology* 2012; 40:1054-61
 Idelevich et al. *Diagnostic Pathology* 2010; 5:70
 Sagiv et al. *Journal of Carcinogenesis* 2009; 8:16-23
 Idelevich et al. *Journal of Histotechnology* 2009; 32:97-105

Micromedic Technologies (TASE: MCTC) is engaged in the development and commercialization of unique solutions addressing real needs prevailing in the field of cancer diagnostics and early cancer detection.

CellDetect® is a Trademark of ZetiQ, a fully-owned subsidiary of Micromedic.



MedNet GmbH, Borkstrasse 10,
48163, Münster, Germany